参考文献
[1]Kenmotsu H, Niho S, Tsuboi M, et al. Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206. J Clin Oncol. 2020 Nov 2:JCO2001806. doi: 10.1200/JCO.20.01806.
[2]van Meerbeeck JP, FennellDA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011 Nov12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7.
[3]Spigel DR, Townley PM,Waterhouse DM, et al. Randomized phase II study of bevacizumab in combinationwith chemotherapy in previously untreated extensive-stage small-cell lungcancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22.doi: 10.1200/JCO.2010.29.3423.
[4]Noda K, Nishiwaki Y,Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide pluscisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan10;346(2):85-91. doi: 10.1056/NEJMoa003034.
[5]Hanna N, Bunn PA Jr,Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin withetoposide/cisplatin in patients with previously untreated extensive-stagedisease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. doi:10.1200/JCO.2005.04.8595.
[6]R.B. Natale, P.N. Lara,K. Chansky. A randomized phase III trial comparing irinotecan/cisplatin with eto-poside/cisplatinin patients with previously untreated extensive-stage small-cell lungcancer[J]. Journal of Clinical Oncology, 2008, 26(15_suppl).DOI:10.1200/jco.2008.26.15_suppl.7512
[7]Schmittel A, Sebastian M,Fischer von Weikersthal L, et al. A German multicenter, randomized phase IIItrial comparing irinotecan-carboplatin with etoposide-carboplatin as first-linetherapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011Aug;22(8):1798-804. doi: 10.1093/annonc/mdq652.
[8]Zatloukal P, Cardenal F,Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M,Thomas M. A multicenter international randomized phase III study comparingcisplatin in combination with irinotecan or etoposide in previously untreatedsmall-cell lung cancer patients with extensive disease. Ann Oncol. 2010Sep;21(9):1810-1816. doi: 10.1093/annonc/mdq036. Epub 2010 Mar 15. PMID:20231298.
[9]Jiang J, Liang X, Zhou X,et al. A meta-analysis of randomized controlled trials comparingirinotecan/platinum with etoposide/platinum in patients with previouslyuntreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010Jun;5(6):867-73. doi: 10.1097/jto.0b013e3181d95c87.
[10]Fink TH, Huber RM,Heigener DF, et al. Topotecan/cisplatin compared with cisplatin/etoposide asfirst-line treatment for patients with extensive disease small-cell lungcancer: final results of a randomized phase III trial. J Thorac Oncol. 2012Sep;7(9):1432-9. doi: 10.1097/JTO.0b013e318260de75.
[11]Postmus PE, Berendsen HH,van Zandwijk N, et al. Retreatment with the induction regimen in small celllung cancer relapsing after an initial response to short term chemotherapy. EurJ Cancer Clin Oncol. 1987 Sep;23(9):1409-11. doi: 10.1016/0277-5379(87)90128-3.
[12]Giaccone G, Ferrati P,Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur JCancer Clin Oncol. 1987 Nov;23(11):1697-9. doi: 10.1016/0277-5379(87)90452-4.
[13]von Pawel J, Schiller JH,Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, andvincristine for the treatment of recurrent small-cell lung cancer. J ClinOncol. 1999 Feb;17(2):658-67. doi: 10.1200/JCO.1999.17.2.658.
[14]Eckardt JR, von Pawel J,Pujol JL, et al. Phase III study of oral compared with intravenous topotecan assecond-line therapy in small-cell lung cancer. J Clin Oncol. 2007 May20;25(15):2086-92. doi: 10.1200/JCO.2006.08.3998.
[15]Masuda N, Fukuoka M,Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatmentof refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992Aug;10(8):1225-9. doi: 10.1200/JCO.1992.10.8.1225.
[16]Smit EF, Fokkema E,Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patientswith small-cell lung cancer. Br J Cancer. 1998;77(2):347-51. doi:10.1038/bjc.1998.54.
[17]Smyth JF, Smith IE, SessaC, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The EarlyClinical Trials Group of the EORTC. Eur J Cancer. 1994;30A(8):1058-60. doi:10.1016/0959-8049(94)90455-3.
[18]Masters GA, Declerck L,Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsedsmall-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J ClinOncol. 2003 Apr 15;21(8):1550-5. doi: 10.1200/JCO.2003.09.130.
[19]van der Lee I, Smit EF, etal. Single-agent gemcitabine in patients with resistant small-cell lung cancer.Ann Oncol. 2001 Apr;12(4):557-61. doi: 10.1023/a:1011104509759.
[20]Einhorn LH, Pennington K,McClean J. Phase II trial of daily oral VP-16 in refractory small cell lungcancer: a Hoosier Oncology Group study. Semin Oncol. 1990 Feb;17(1 Suppl2):32-5.
[21]Johnson DH, Greco FA,Strupp J, et al. Prolonged administration of oral etoposide in patients withrelapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol.1990 Oct;8(10):1613-7. doi: 10.1200/JCO.1990.8.10.1613.
[22]Jassem J,Karnicka-Młodkowska H, van Pottelsberghe C, et al. Phase II study ofvinorelbine (Navelbine) in previously treated small cell lung cancer patients.EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29A(12):1720-2. doi:10.1016/0959-8049(93)90112-s.
[23]Furuse K, Kubota K,Kawahara M, et al. Phase II study of vinorelbine in heavily previously treatedsmall cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology.1996 Mar-Apr;53(2):169-72. doi: 10.1159/000227555.
[24]Pietanza MC, Kadota K,Huberman K, et al. Phase II trial of temozolomide in patients with relapsedsensitive or refractory small cell lung cancer, with assessment ofmethylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res.2012 Feb 15;18(4):1138-45. doi: 10.1158/1078-0432.CCR-11-2059.
[25]Zauderer MG, Drilon A,Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patientswith relapsed small cell lung cancers with assessment of methylguanine-DNAmethyltransferase. Lung Cancer. 2014 Nov;86(2):237-40. doi:10.1016/j.lungcan.2014.08.007.